Silence Therapeutics plc Current Accrued Expenses And Other Current Liabilities
Silence Therapeutics plc (SLNCF) had Current Accrued Expenses And Other Current Liabilities of GBP 8.85 million as of 2023-12-31, per its 20-F filed 2024-03-13.
Discontinued › Notes
ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities · last filed 2024-03-13
- 2023-12-31: Current Accrued Expenses And Other Current Liabilities 8.85M GBP.
- 2022-12-31: Current Accrued Expenses And Other Current Liabilities 8.39M GBP.
- 2021-12-31: Current Accrued Expenses And Other Current Liabilities 6.21M GBP.
- 2020-12-31: Current Accrued Expenses And Other Current Liabilities 4.80M GBP.
| Period end | Current Accrued Expenses And Other Current Liabilities |
|---|---|
| 2023-12-31 | 8.85M GBP 20-F · filed 2024-03-13 |
| 2022-12-31 | 8.39M GBP 20-F · filed 2024-03-13 |
| 2021-12-31 | 6.21M GBP 20-F · filed 2023-03-15 |
| 2020-12-31 | 4.80M GBP 20-F · filed 2022-03-17 |
| 2019-12-31 | 4.74M GBP 20-F/A · filed 2021-04-29 |
| 2018-12-31 | 2.49M GBP 20-F/A · filed 2021-04-29 |